{"corpus_id":199663144,"paper_sha":"14fd1f346a5b9136c39da767600fda2069df9661","doi":"10.1159/000502041","arxiv_id":null,"pmid":31412332,"pmcid":null,"mag_id":2968480065,"dblp_id":null,"acl_id":null,"title":"Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)","year":2019,"publication_date":"2019-08-14","venue":"Ophthalmologica","journal":{"name":"Ophthalmologica","pages":"123 - 162","volume":"242"},"journal_issn":null,"journal_title":null,"publication_types":[],"pubmed_pub_types":["Practice Guideline","Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":164,"citation_count":224,"influential_citation_count":16,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Angiogenesis Inhibitors","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D020533"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Fluorescein Angiography","mj":false,"ui":"D005451"},{"d":"Fundus Oculi","mj":false,"ui":"D005654"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Intravitreal Injections","mj":false,"ui":"D058449"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Ophthalmology","mj":true,"ui":"D009885"},{"d":"Retina","mj":false,"qs":[{"q":"diagnostic imaging","mj":true,"ui":"Q000000981"}],"ui":"D012160"},{"d":"Retinal Vein Occlusion","mj":false,"qs":[{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D012170"},{"d":"Societies, Medical","mj":true,"ui":"D012955"},{"d":"Specialization","mj":true,"ui":"D013038"},{"d":"Tomography, Optical Coherence","mj":false,"ui":"D041623"},{"d":"Visual Acuity","mj":true,"ui":"D014792"}],"chemicals":[{"n":"Angiogenesis Inhibitors","ui":"D020533","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.karger.com/Article/Pdf/502041","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/14fd1f346a5b9136c39da767600fda2069df9661","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"The high prevalence of cardiovascular disease particularly in the elderly population is associated with retinal vascular disease. Retinal vein occlusions represent severe disturbances of the hypoxia-sensitive neurosensory retina. Acute and excessive leakage leads to the diagnostic hallmarks of retinal hemorrhage and edema with substantial retinal thickening. Advanced diagnostic tools such as OCT angiography allow to evaluate retinal ischemia and identify the risk for late complications and will soon reach clinical routine besides fluorescein angiography. Accordingly, the duration of non-perfusion is a crucial prognostic factor requiring timely therapeutic intervention. With immediate inhibition of vascular leakage, anti-VEGF substances excel as treatment of choice. Multiple clinical trials with optimal potential for functional benefit or a lesser regenerative spectrum have evaluated aflibercept, ranibizumab, and bevacizumab. As retinal vein occlusion is a chronic disease, long-term monitoring should be individualized to combine maintenance with practicability. While steroids may be considered in patients with systemic cardiovascular risk, surgery remains advisable only for very few patients. Destructive laser treatment is an option if reliable monitoring is not feasible. Ophthalmologists are also advised to perform a basic systemic workup to recognize systemic concomitants. The current edition of the EURETINA guidelines highlights the state-of-the-art recommendations based on the literature and expert opinions in retinal vein occlusion.","claims":[{"public_id":"cl_484added924af31e78fdb8a1f1f6d69b","status":"active","text":"Anti-VEGF substances are the treatment of choice for immediate inhibition of vascular leakage in retinal vein occlusion.","confidence":0.85,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_484added924af31e78fdb8a1f1f6d69b"},{"public_id":"cl_57f4dcd84d6e463cf2793eb37751e599","status":"active","text":"Duration of non-perfusion is a crucial prognostic factor in retinal vein occlusion that requires timely therapeutic intervention.","confidence":0.85,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_57f4dcd84d6e463cf2793eb37751e599"},{"public_id":"cl_adfa623d03652c52e76cecf3cbb1dc26","status":"active","text":"OCT angiography allows evaluation of retinal ischemia and identification of the risk for late complications in retinal vein occlusion, alongside fluorescein angiography.","confidence":0.75,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_adfa623d03652c52e76cecf3cbb1dc26"}],"concepts":[{"public_id":"co_0322cad2666b1c27029c2031aa74830c","status":"active","name":"anti-VEGF substances","description":"Pharmacological agents that inhibit vascular endothelial growth factor to reduce vascular leakage in retinal vein occlusion.","types":["drug class"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0322cad2666b1c27029c2031aa74830c"},{"public_id":"co_0d88104cbba877624615d61e6dd418c2","status":"active","name":"non-perfusion","description":"Loss of retinal blood flow whose duration serves as a prognostic factor in retinal vein occlusion.","types":["phenomenon"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0d88104cbba877624615d61e6dd418c2"},{"public_id":"co_0f20d3a69088f65c2ddd384c5a43789e","status":"active","name":"retinal ischemia","description":"A state of insufficient blood supply to the retina evaluated with advanced diagnostic imaging in retinal vein occlusion.","types":["phenomenon"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0f20d3a69088f65c2ddd384c5a43789e"},{"public_id":"co_127a3e6417e76877c6f16cb8cfdd824b","status":"active","name":"fluorescein angiography","description":"An established angiographic imaging method used alongside OCT angiography to assess the retinal vasculature.","types":["diagnostic method"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_127a3e6417e76877c6f16cb8cfdd824b"},{"public_id":"co_3af6821415a33543dc782f3a9faf3677","status":"active","name":"ranibizumab","description":"An anti-VEGF drug evaluated in clinical trials for treating retinal vein occlusion.","types":["drug"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_3af6821415a33543dc782f3a9faf3677"},{"public_id":"co_4e4697c2fbb40d82a086b02d3e8078c0","status":"active","name":"vascular leakage","description":"Abnormal leakage from retinal vessels that drives hemorrhage and edema in retinal vein occlusion and is targeted by anti-VEGF therapy.","types":["phenomenon"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_4e4697c2fbb40d82a086b02d3e8078c0"},{"public_id":"co_68992a4d19ef11d1c93831cff1ac3705","status":"active","name":"OCT angiography","description":"An advanced imaging technique used to evaluate retinal ischemia and identify risk of late complications in retinal vascular disease.","types":["diagnostic method"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_68992a4d19ef11d1c93831cff1ac3705"},{"public_id":"co_72d0a7346651d145420a74c3679f6a07","status":"active","name":"bevacizumab","description":"An anti-VEGF drug evaluated in clinical trials for treating retinal vein occlusion.","types":["drug"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_72d0a7346651d145420a74c3679f6a07"},{"public_id":"co_9d58eb2e57deeb30cf814910ae07f965","status":"active","name":"retinal vein occlusion","description":"A retinal vascular disease caused by obstruction of venous blood flow in the retina, leading to hemorrhage and edema.","types":["condition"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_9d58eb2e57deeb30cf814910ae07f965"},{"public_id":"co_a2c6ba193c2a2b578819b340ea078448","status":"active","name":"EURETINA guidelines","description":"Clinical practice guidelines issued by the European Society of Retina Specialists for the management of retinal vein occlusion.","types":["guideline"],"aliases":["European Society of Retina Specialists"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_a2c6ba193c2a2b578819b340ea078448"},{"public_id":"co_be0c78399076dc38eb4843c9d6ce6065","status":"active","name":"aflibercept","description":"An anti-VEGF drug evaluated in clinical trials for treating retinal vein occlusion.","types":["drug"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_be0c78399076dc38eb4843c9d6ce6065"},{"public_id":"co_df610f5ea85b6505427dca533ef03bc8","status":"active","name":"retinal hemorrhage","description":"Bleeding within the retina that is a diagnostic hallmark of acute retinal vein occlusion.","types":["clinical sign"],"aliases":[],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_df610f5ea85b6505427dca533ef03bc8"}],"external_ids":{"DOI":"10.1159/000502041","ArXiv":null,"PubMed":31412332,"PubMedCentral":null,"MAG":2968480065,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.karger.com/Article/Pdf/502041","landing_url":"https://www.semanticscholar.org/paper/14fd1f346a5b9136c39da767600fda2069df9661","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631379,"paper_uid":"d4f79b42-ae88-47e5-bdb3-34ee714f90e4","canonical_identity":{"paper_id":631379,"paper_uid":"d4f79b42-ae88-47e5-bdb3-34ee714f90e4","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/199663144"}